AI drug development shifts toward causal targets and controlled biology

Ono Pharma’s option on Aitia-generated neurological targets provides commercial validation, while Formation Bio targets clinical-development bottlenecks such as enrollment and site selection. Organoid, imaging, and robotics systems reporting 87% balanced accuracy across 74 drugs point toward reproducible experimental control; most other AI pipelines remain preclinical, with clinical and regulatory validation unresolved.